MX344473B - Composicion farmaceutica acuosa semisolida que contiene tapentadol. - Google Patents

Composicion farmaceutica acuosa semisolida que contiene tapentadol.

Info

Publication number
MX344473B
MX344473B MX2013010100A MX2013010100A MX344473B MX 344473 B MX344473 B MX 344473B MX 2013010100 A MX2013010100 A MX 2013010100A MX 2013010100 A MX2013010100 A MX 2013010100A MX 344473 B MX344473 B MX 344473B
Authority
MX
Mexico
Prior art keywords
pharmaceutical composition
composition containing
aqueous pharmaceutical
containing tapentadol
semisolid aqueous
Prior art date
Application number
MX2013010100A
Other languages
English (en)
Other versions
MX2013010100A (es
Inventor
Schiller Marc
Reinhold Ulrich
Wulsten Eva
Karine Katrien Inghelbrecht Sabine
Carolus Augusta Embrechts Roger
Feil Ulrich
Original Assignee
Gruenenthal Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gruenenthal Gmbh filed Critical Gruenenthal Gmbh
Publication of MX2013010100A publication Critical patent/MX2013010100A/es
Publication of MX344473B publication Critical patent/MX344473B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Emergency Medicine (AREA)
  • Dispersion Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)

Abstract

La invención se refiere a una composición farmacéutica acuosa semisólida que contiene tapentadol o una sal fisiológicamente aceptable del mismo.
MX2013010100A 2011-03-04 2012-03-02 Composicion farmaceutica acuosa semisolida que contiene tapentadol. MX344473B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161449329P 2011-03-04 2011-03-04
EP11003603 2011-05-03
PCT/EP2012/000906 WO2012119729A1 (en) 2011-03-04 2012-03-02 Semisolid aqueous pharmaceutical composition containing tapentadol

Publications (2)

Publication Number Publication Date
MX2013010100A MX2013010100A (es) 2013-10-01
MX344473B true MX344473B (es) 2016-12-16

Family

ID=44652117

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2013010100A MX344473B (es) 2011-03-04 2012-03-02 Composicion farmaceutica acuosa semisolida que contiene tapentadol.

Country Status (24)

Country Link
US (3) US9446008B2 (es)
EP (3) EP3766489B1 (es)
JP (3) JP6027549B2 (es)
KR (2) KR102039320B1 (es)
CN (1) CN103501774A (es)
AU (2) AU2012224954C1 (es)
BR (1) BR112013022556A8 (es)
CA (1) CA2828637C (es)
CY (1) CY1119725T1 (es)
DK (1) DK2680834T3 (es)
EA (2) EA025194B1 (es)
ES (2) ES2654407T3 (es)
HR (1) HRP20171836T1 (es)
HU (1) HUE037491T2 (es)
IL (2) IL227826B (es)
LT (1) LT2680834T (es)
MX (1) MX344473B (es)
NO (1) NO2680834T3 (es)
PL (1) PL2680834T3 (es)
PT (2) PT3766489T (es)
RS (1) RS56692B1 (es)
SI (1) SI2680834T1 (es)
WO (1) WO2012119729A1 (es)
ZA (1) ZA201306480B (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS56692B1 (sr) 2011-03-04 2018-03-30 Gruenenthal Gmbh Polučvrsta vodena farmaceutska kompozicija koja sadrži tapentadol
PT2680832T (pt) 2011-03-04 2019-10-28 Gruenenthal Gmbh Formulação farmacêutica aquosa de tapentadol para administração oral
US8997860B2 (en) 2011-08-05 2015-04-07 Halliburton Energy Services, Inc. Methods for monitoring the formation and transport of a fracturing fluid using opticoanalytical devices
US9395306B2 (en) 2011-08-05 2016-07-19 Halliburton Energy Services, Inc. Methods for monitoring fluids within or produced from a subterranean formation during acidizing operations using opticoanalytical devices
US20140076550A1 (en) 2012-09-14 2014-03-20 Halliburton Energy Services, Inc. Systems and Methods for Detecting Microannulus Formation and Remediation
US8619256B1 (en) 2012-09-14 2013-12-31 Halliburton Energy Services, Inc. Systems and methods for monitoring the properties of a fluid cement composition in a flow path
US9228940B2 (en) 2012-09-14 2016-01-05 Halliburton Energy Services, Inc. Systems, methods, and apparatuses for in situ monitoring of cement fluid compositions and setting processes thereof
EP3027214A1 (en) * 2013-08-02 2016-06-08 ratiopharm GmbH Composition comprising tapentadol in a dissolved form
EP2845625A1 (en) 2013-09-04 2015-03-11 Grünenthal GmbH Tapentadol for use in the treatment of fibromyalgia and chronic fatigue syndrome
PT3479823T (pt) 2015-03-27 2020-09-29 Gruenenthal Gmbh Formulação estável para administração parentérica de tapentadol
MX2019003257A (es) * 2016-09-23 2019-06-10 Gruenenthal Gmbh Formulacion estable para la administracion parenteral de tapentadol.
WO2020020879A1 (en) * 2018-07-24 2020-01-30 Dr. August Wolff Gmbh & Co. Kg Arzneimittel Topical emulsion of an anticholinergic compound

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4775678A (en) * 1984-10-01 1988-10-04 Schering Corporation Clotrimazole cream
DE4426245A1 (de) 1994-07-23 1996-02-22 Gruenenthal Gmbh 1-Phenyl-3-dimethylamino-propanverbindungen mit pharmakologischer Wirkung
US6183758B1 (en) * 1998-01-29 2001-02-06 Highland Laboratories, Inc. Phytochemicals, nutrients & medication absorption &/or treatment
US6399087B1 (en) 2000-12-20 2002-06-04 Amphastar Pharmaceuticals, Inc. Propofol formulation with enhanced microbial inhibition
DE10109763A1 (de) 2001-02-28 2002-09-05 Gruenenthal Gmbh Pharmazeutische Salze
US20050176790A1 (en) 2001-02-28 2005-08-11 Johannes Bartholomaus Pharmaceutical salts
PE20030527A1 (es) 2001-10-24 2003-07-26 Gruenenthal Chemie Formulacion farmaceutica con liberacion retardada que contiene 3-(3-dimetilamino-1-etil-2-metil-propil) fenol o una sal farmaceuticamente aceptable del mismo y tabletas para administracion oral que la contienen
US20030203055A1 (en) 2002-03-15 2003-10-30 Cypress Bioscience, Inc. Methods of treating visceral pain syndromes
US20030191187A1 (en) 2002-04-01 2003-10-09 Lee Fang Yu Injectable pharmaceutical composition containing a non-steroidal anti-inflammatory drug and method for preparing the same
KR20050046776A (ko) 2002-09-13 2005-05-18 사이덱스 인크 유도체화된 사이클로덱스트린으로 안정화한 수성 충전조성물을 포함하는 캅셀
US20040180915A1 (en) 2003-03-14 2004-09-16 Xanodyne Pharmacal, Inc. Methadone-containing compositions for parenteral administration and method of use thereof
WO2005112926A1 (en) 2004-05-17 2005-12-01 Pharmacofore, Inc. Compositions and methods for treating or preventing pain
DK1612203T3 (da) 2004-06-28 2007-12-03 Gruenenthal Gmbh Krystallinske former af (-)-(1R,2R)-3-(3-dimethylamino-1-ethyl-2-methylpropyl)-phenolhydrochlorid
CA2572352A1 (en) 2004-07-01 2006-01-12 Gruenenthal Gmbh Oral dosage form safeguarded against abuse containing (1r,2r)-3-(3-dimethylamino-1-ethyl-2-methyl-propyl)phenol
MX2007013583A (es) 2005-04-28 2008-03-13 Theraquest Biosciences Llc Metodos y composiciones para tratar el dolor.
TWI329334B (en) 2005-12-02 2010-08-21 Chung Shan Inst Of Science Manufacture method of electromagnetic interference layer for the plasma display panel
WO2007127158A2 (en) * 2006-04-25 2007-11-08 Croda, Inc Modification of percutaneous absorption of topically active materials
ES2358763T3 (es) 2006-04-28 2011-05-13 Grünenthal GmbH Combinación farmacéutica que comprende 3-(3-dimetilamino-1-etil-2-metilpropil)fenol y un nsaid.
PT2012764E (pt) 2006-04-28 2011-02-02 Gruenenthal Gmbh Combinação farmacêutica que compreende 3-(3-dimetilamino-1- etil-2-metilpropil)fenol e paracetamol
DK2046726T3 (da) 2006-07-24 2010-05-10 Janssen Pharmaceutica Nv Fremstilling af (2R,3R)-3-3-methoxyphenyl)-N,N, 2-trimethylpentanamin
DE102007012165A1 (de) * 2007-03-12 2008-09-18 Grünenthal GmbH Verwendung von 1-Phenyl-3-dimethylamino-propanverbindungen zur Therapie des Neuropathieschmerzes
EP1985292A1 (en) 2007-04-23 2008-10-29 Grünenthal GmbH Titration of tapentadol
LT2596784T (lt) 2007-11-23 2017-03-27 Grünenthal GmbH Tapentadolio kompozicijos
EP2249811A1 (en) 2008-01-25 2010-11-17 Grünenthal GmbH Pharmaceutical dosage form
HUE047438T2 (hu) * 2008-10-30 2020-04-28 Gruenenthal Gmbh Új és potens tapentadol dózisformák
WO2010100477A2 (en) 2009-03-03 2010-09-10 Shire Llc Amino acid and peptide carbamate prodrugs of tapentadol and uses thereof
US20100272815A1 (en) * 2009-04-28 2010-10-28 Actavis Group Ptc Ehf Amorphous form of tapentadol hydrochloride
WO2011083304A1 (en) * 2010-01-05 2011-07-14 Shire Llc Prodrugs of opioids and uses thereof
RU2553350C2 (ru) * 2010-03-30 2015-06-10 Фосфейдженикс Лимитед Трансдермальные пластыри
GB201006200D0 (en) 2010-04-14 2010-06-02 Ayanda As Composition
US20120270848A1 (en) * 2010-10-22 2012-10-25 Galleon Pharmaceuticals, Inc. Novel Compositions and Therapeutic Methods Using Same
RS56692B1 (sr) 2011-03-04 2018-03-30 Gruenenthal Gmbh Polučvrsta vodena farmaceutska kompozicija koja sadrži tapentadol

Also Published As

Publication number Publication date
HUE037491T2 (hu) 2018-09-28
EA201600442A1 (ru) 2017-02-28
PL2680834T3 (pl) 2018-03-30
NO2680834T3 (es) 2018-03-17
PT3766489T (pt) 2022-04-07
JP2017039756A (ja) 2017-02-23
BR112013022556A8 (pt) 2018-01-16
LT2680834T (lt) 2018-01-10
CN103501774A (zh) 2014-01-08
JP2014506900A (ja) 2014-03-20
KR20140013020A (ko) 2014-02-04
EP3766489B1 (en) 2022-03-16
RS56692B1 (sr) 2018-03-30
EA201300988A1 (ru) 2014-06-30
AU2012224954C1 (en) 2017-04-06
EA025194B1 (ru) 2016-11-30
CA2828637A1 (en) 2012-09-13
WO2012119729A1 (en) 2012-09-13
AU2012224954A1 (en) 2013-09-19
KR101911362B1 (ko) 2018-10-25
JP6027549B2 (ja) 2016-11-16
AU2017200040B2 (en) 2018-09-06
JP2018065839A (ja) 2018-04-26
BR112013022556A2 (pt) 2016-12-06
IL227826B (en) 2018-04-30
MX2013010100A (es) 2013-10-01
US20160346229A1 (en) 2016-12-01
JP6670283B2 (ja) 2020-03-18
PT2680834T (pt) 2018-01-25
DK2680834T3 (en) 2017-12-04
EA033171B1 (ru) 2019-09-30
JP6259042B2 (ja) 2018-01-10
CA2828637C (en) 2019-06-11
EP3290029B1 (en) 2020-09-02
KR102039320B1 (ko) 2019-11-01
CY1119725T1 (el) 2018-06-27
HRP20171836T1 (hr) 2017-12-29
EP2680834B1 (en) 2017-10-18
US9446008B2 (en) 2016-09-20
IL227826A0 (en) 2013-09-30
EP2680834A1 (en) 2014-01-08
EP3290029A1 (en) 2018-03-07
US20120225950A1 (en) 2012-09-06
ZA201306480B (en) 2014-05-28
AU2012224954B2 (en) 2016-10-20
SI2680834T1 (en) 2018-01-31
KR20180116463A (ko) 2018-10-24
EP3766489A1 (en) 2021-01-20
US20180133174A1 (en) 2018-05-17
ES2654407T3 (es) 2018-02-13
AU2017200040A1 (en) 2017-02-02
IL258357A (en) 2018-05-31
ES2910085T3 (es) 2022-05-11

Similar Documents

Publication Publication Date Title
EA033171B1 (ru) Полутвёрдая фармацевтическая композиция на водной основе, содержащая тапентадол
IN2014CN02616A (es)
UA111717C2 (uk) Склад для перорального введення і ліпофільні солі метилналтрексону
MX349224B (es) Composicion farmaceutica para uso en el tratamiento de una enfermedad neurodegenerativa.
AP2014007399A0 (en) Phenyl-3-AZA-bicycloÄ3.1.0Ühex-3-YL-methanones andthe use thereof as medicament
EP2702054A4 (en) NOVEL BISAMINOQUINOLINE COMPOUNDS, PHARMACEUTICAL COMPOSITIONS PREPARED THEREFROM, AND USE THEREOF
MX348831B (es) Administración parenteral de tapentadol.
MX356728B (es) Combinación farmacéutica para usar en el tratamiento de pacientes que padecen diabetes de tipo 2.
JO3154B1 (ar) عوامل مضادة لـ trpv4
MX2013008500A (es) Disialillacto-n-tetraosa (dslnt) o variantes, isomeros, analogos y derivados de la misma para prevenir o inhibir la enfermedad del intestino.
MX2013002948A (es) Composiciones farmaceuticas y nutraceuticas de acido abscisico.
EP2702989A4 (en) STABLE PHARMACEUTICAL COMPOSITION
MX2014010433A (es) Nueva forma cristalina de sulfato de sitagliptina.
HK1197176A1 (en) Topical ophthalmological pharmaceutical composition containing regorafenib
MX348786B (es) Agentes osmoticos de polisacarido esterificado.
PT2755635E (pt) Composições aquosas que compreendem arbecacina
EP2609933A4 (en) AQUEOUS COMPOSITION FOR ADMINISTRATION
PL2851075T3 (pl) Preparat zawierający pochodną 6,7-nienasyconego-7-karbamoilomorfinanu
GB201420685D0 (en) Aqueous disinfectant composition
MX2014004210A (es) Derivados de 2-oxo-piperidinilo.
HK1250664A1 (zh) 含有他噴他多的半固體水性藥物組合物
MX2012014969A (es) Composiciones farmaceuticas estables de amlodipina con telmisartan.
UA111066C2 (uk) Композиція, яка містить шелак та/або його сіль і натрію крохмальгліколят
EP2627655A4 (en) THERAPEUTIC 5,6,5-TRICYCLIC ANALOGUES

Legal Events

Date Code Title Description
FG Grant or registration
HH Correction or change in general